Researchers used real-world data to determine the impact of hepatic fibrosis on the effectiveness of sofosbuvir/velpatasvir treatment in an Asian population with hepatitis C virus infection.
Investigators assessed factors affecting HBsAg seroclearance in individuals with hepatitis B virus infection.
Researchers assessed the cost-effectiveness of universal adult screening for chronic hepatitis B virus infection.
Investigators assessed the effectiveness of hepatitis C virus treatment-as-prevention in a prison setting.
Investigators assessed the safety and efficacy of apatinib in pretreated hepatocellular carcinoma and its effects on overall survival.
A team of researchers sought to compare the seroprotection rate of a hepatitis B virus tri-antigenic vaccine with that of a mono-antigenic vaccine in adults.
The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection.
HyperHEP B is the Grifol’s new formulation of its hepatitis B immune globulin.
Researchers assessed the influence of direct-acting antivirals on gut microbiota by analyzing microbial diversity and composition in patients with hepatitis C virus infection with or without HIV.
Patients with current or past HBV infection are not at greater risk for liver injury or mortality during COVID-19 infection.
Investigators analyzed the safety of tenofovir disoproxil fumarate therapy during the third trimester of pregnancy.
Researchers reviewed the effects of direct-acting antiviral therapies on the extrahepatic manifestations of HCV.
Researchers aimed to characterize serological, virological, and histological profiles during and after multidose ARC-520 treatment in patients with chronic HBV.
Investigators conducted an international, multicenter meta-analysis to assess HCC recurrence risk in patients treated with DAAs.
Researchers launched a simplified model of HCV care through decentralized health services within rural Cambodia.
The researchers’ objective was to determine the prevalence of HCV antibodies among MSM with and without HIV, as well as factors associated with HCV infection among MSM.
All five patients were hospitalized but have since recovered.
A team of investigators examined differences in outcomes according to sex in risk for acute coronary syndrome, end-stage renal disease, and ischemic stroke by treatment and response in a large US-based multisite cohort of patients with hepatitis C virus infection.
While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.
Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.